指南与共识儿科与产科急症消化、代谢与肾脏急症

第385号意见:盆腔检查的适应证

No. 385-Indications for Pelvic Examination.
指南 / 共识 · J Obstet Gynaecol Can · 2019-01-01
一句话结论加拿大妇产科医师学会(SOGC)等机构联合发布委员会意见,明确有妇科症状女性应行盆腔检查的适应证,并指出无症状平均风险女性筛查性盆腔检查证据不足。

该委员会意见由SOGC、加拿大家庭医师学院(CFPC)和加拿大妇科肿瘤学会(GOC)共同批准,旨在明确成人女性(18岁及以上)盆腔检查的适应证。检索PubMed和Medline(2018年5—6月)共纳入66篇文献,未进行正式系统评价。核心结论:有妇科症状女性应行相应盆腔检查成分以识别良恶性疾病(强推荐,低质量证据);无症状平均风险女性筛查性盆腔检查用于非宫颈癌或良性疾病证据不足,可考虑与宫颈细胞学采样间隔同步进行(弱推荐,极低质量证据)。该意见强调不应将国家或国际声明解读为盆腔检查无关或可省略有症状女性的检查。

要点

  • 有妇科症状(外阴不适、阴道分泌物、异常子宫出血、不孕、盆腔器官脱垂、尿失禁、新发不明原因胃肠道症状、盆腔痛、性交痛等)的女性应行相应盆腔检查成分以识别良恶性疾病(强推荐,低质量证据)。
  • 无症状平均风险女性筛查性盆腔检查用于非宫颈癌妇科恶性肿瘤或良性疾病证据不足;可考虑与宫颈细胞学采样间隔同步进行视觉、窥器及双合诊检查(弱推荐,极低质量证据)。
  • 70岁以上不再需要宫颈细胞学筛查的无症状女性,可考虑继续定期检查外阴、会阴和肛门以识别未被患者报告或识别的良恶性疾病;检查频率证据不足(弱推荐,低质量证据)。
  • 有妇科恶性肿瘤个人史、增加妇科恶性肿瘤风险的遗传学诊断或宫内己烯雌酚暴露史的女性,可能在无症状时受益于更频繁的筛查性盆腔检查;筛查间隔证据不足,应遵循省级/地区指南和专家意见(弱推荐,极低质量证据)。
  • 无症状女性沙眼衣原体和淋病奈瑟菌的非侵入性和自采样筛查是可接受的,但出现症状时需行盆腔检查包括视觉检查、窥器检查和双合诊。

适用人群与场景

  • 成人女性(18岁及以上),包括有妇科症状和无妇科症状者。
  • 适用场景包括妇科医生、产科医生、家庭医生和急诊医生;护士(注册护士和执业护士);助产士(临床实践助产士和助产学员);医学学员(医学生、住院医师和专科培训医师);以及其他所有照护女性的卫生保健提供者。

处置流程与药物剂量

  • 有妇科症状的女性(包括但不限于外阴不适、阴道分泌物、绝经前异常出血、绝经后出血、不孕、盆腔器官脱垂症状、尿失禁、新发不明原因胃肠道症状如腹痛、腹围增大/腹胀、进食困难/早饱、盆腔痛或性交痛)应行相应盆腔检查成分以识别良恶性疾病(强推荐,低质量证据)。
  • 卫生保健提供者可在处方激素替代治疗/绝经激素治疗前讨论行基线盆腔检查(包括视觉检查和双合诊)的风险与获益(弱推荐,极低质量证据)。
  • 卫生保健从业者应按照省级/地区指南行宫颈细胞学癌症筛查(强推荐,强证据)。
  • 对于无症状、恶性肿瘤平均风险的健康女性,筛查性盆腔检查用于非宫颈妇科恶性肿瘤或任何良性妇科疾病证据不足;但从业者可考虑按照省级/地区指南推荐的宫颈细胞学采样间隔同步进行筛查性盆腔检查,包括视觉、窥器和双合诊检查,该做法可能识别患者未识别或报告的临床重要良恶性疾病(弱推荐,极低质量证据)。
  • 70岁以上不再需要宫颈细胞学筛查的女性,从业者应考虑继续定期筛查无症状女性的外阴疾病,检查外阴、会阴和肛门以识别该人群未识别的良恶性疾病;检查频率证据不足(弱推荐,低质量证据)。
  • 有妇科恶性肿瘤个人史、增加妇科恶性肿瘤风险的遗传学诊断或宫内己烯雌酚暴露史的女性,可能在无症状时受益于更频繁的筛查性盆腔检查以识别早期原发、复发或转移性恶性肿瘤;因证据不足以定义筛查间隔,应遵循省级/地区指南和专家意见(弱推荐,极低质量证据)。
  • 无症状女性沙眼衣原体和淋病奈瑟菌的非侵入性和自采样筛查是可接受的,但出现症状时需行盆腔检查,包括视觉检查、窥器检查和双合诊。

研究设计与关键结果

  • 该文件为SOGC委员会意见,由主要作者起草并达成一致,经SOGC、CFPC和GOC各自代表委员会审查后批准发布。
  • 证据检索于2018年5—6月在PubMed和Medline进行,限定英语文献和人类受试者,无发表时间截止;共纳入66篇文献。
  • 证据质量采用GRADE方法学框架评级(表1和表2);因证据匮乏和讨论的亚主题众多,未对所有主题进行正式系统评价。
  • 该委员会意见将在发布后5年自动审查以确定是否全部或部分更新;若期间发表新的高影响力研究,可提前审查。

证据类型、等级与局限

  • 证据类型:委员会意见(指南/共识),基于文献检索和专家意见,采用GRADE方法学框架进行证据质量评级。
  • 推荐强度与证据质量照录原文:有症状女性行盆腔检查为强推荐、低质量证据;激素替代治疗前讨论基线盆腔检查为弱推荐、极低质量证据;宫颈细胞学筛查为强推荐、强证据;无症状平均风险女性筛查性盆腔检查为弱推荐、极低质量证据;70岁以上女性外阴检查为弱推荐、低质量证据;高危女性更频繁筛查为弱推荐、极低质量证据。
  • 原文指出:除宫颈细胞学筛查的窥器检查外,迄今尚无研究充分评价盆腔检查任何成分作为任何类型妇科恶性肿瘤筛查方法的作用;因此对其他适应证的普遍推荐或反对只能基于专家意见和低质量证据。
  • 原文指出:无症状平均风险女性在获取宫颈细胞学样本时行视觉和双合诊检查可能增加价值,但迄今研究不充分,对卵巢和外阴恶性肿瘤可能有正面影响,需进一步研究;这些潜在获益应与患者不适和假阳性/假阴性导致的不适当 reassurance 或不必要检查/干预等潜在危害权衡。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 有妇科症状的女性不应因国家或国际盆腔检查声明而被省略盆腔检查;应行相应盆腔检查成分以识别良恶性疾病(强推荐,低质量证据)。
  • 无症状平均风险女性,从业者可考虑按照省级/地区指南的宫颈细胞学采样间隔同步进行筛查性盆腔检查(包括视觉、窥器和双合诊),但须权衡潜在获益与患者不适及假阳性/假阴性风险(弱推荐,极低质量证据)。
  • 70岁以上不再需要宫颈细胞学筛查的无症状女性,可考虑继续定期检查外阴、会阴和肛门以识别未识别的良恶性疾病;检查频率证据不足(弱推荐,低质量证据)。
  • 有妇科恶性肿瘤个人史、遗传学高风险或宫内己烯雌酚暴露史的女性,可能在无症状时受益于更频繁的筛查性盆腔检查,筛查间隔应遵循省级/地区指南和专家意见(弱推荐,极低质量证据)。

指南或共识出处

  • SOGC Committee Opinion No. 385, Indications for Pelvic Examination, Society of Obstetricians and Gynaecologists of Canada (SOGC), 经Canadian Society of Gynaecologic Oncology (GOC)和College of Family Physicians of Canada (CFPC)批准。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The primary objective of this document is to clarify the indications for pelvic examination.

INTENDED USERS: Physicians, including gynaecologists, obstetricians, family physicians, and emergency physicians; nurses, including registered nurses and nurse practitioners; midwives, including midwives in clinical practice and midwifery trainees; medical trainees, including medical students, residents, and fellows; and all other health care providers who care for women.

TARGET POPULATION: This publication provides evidence and expert-based recommendations for pelvic examination in adult women (18 years and older) both with and without gynaecologic symptoms.

OUTCOMES: This publication clarifies indications for pelvic examination in the context of recently published national task force statements on the utility of pelvic examination. We aim to ensure that women who have clinical indications for examination receive proper clinical investigation with minimal delays to diagnosis of treatable disease.

EVIDENCE: For this committee opinion, relevant studies were identified in PubMed and Medline using the following terms, either alone or in combination, with the search limited to English-language materials and human subjects and no publication date cut-off: pelvic examination, bimanual examination, speculum examination, rectovaginal examination, ovarian cancer screening, asymptomatic women, periodic health examination. The search was performed in May and June 2018. Relevant evidence was selected for inclusion in the following order: meta-analyses, systematic reviews, guidelines and national task force statements, randomized controlled trials, prospective cohort studies, observational studies, non-systematic reviews, case series, and reports. Additional articles were identified by cross-referencing the identified publications. A formal systematic review was not conducted for all topics discussed due to the paucity of evidence and number of different subtopics discussed. The total number of publications included in this review was 66.

VALIDATION METHODS: The content and recommendations were drafted and agreed upon by the principal authors. The Boards of the Society of Gynecologic Oncology of Canada (GOC), the College of Family Physicians of Canada (CFPC), and the Society of Obstetricians and Gynaecologists of Canada (SOGC) approved the final draft for publication after review by their respective representative committees. The quality of evidence was rated using the criteria described in the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology framework (Tables 1 and 2). The Summary of Findings is available upon request.

BENEFITS, HARMS, AND COSTS: This committee opinion should benefit all women with and without gynaecologic symptoms who present to gynaecologists and primary care practitioners. It will help guide practitioners in identifying indications for pelvic examination to reduce unnecessary examination with related potential harm while also increasing indicated examination to reduce delays in diagnosis of treatable gynaecologic conditions.

GUIDELINE UPDATE: This SOGC Committee Opinion will be automatically reviewed 5 years after publication to determine if all or part of the committee opinion should be updated. However, this review may be performed earlier if new high-impact research is published in the interim.

SUMMARY STATEMENTS: 1. National and international statements and guidelines on pelvic examination should not be interpreted to suggest that the pelvic examination is irrelevant or noncontributory to physical assessment or that the pelvic examination in symptomatic women should be omitted. 2. Pelvic examination may include visual inspection, speculum examination, bimanual examination, single digit examination, and/or rectovaginal examination depending on the indication for examination. 3. No study published to date has adequately evaluated any component of the pelvic examination as a screening method for any type of malignant gynaecologic disease, except for the speculum examination for cervical cancer cytology screening. As such, any universal recommendations for or against pelvic examinations for other indications can only be made based on expert opinion and low-quality evidence. 4. In asymptomatic women at average risk for cervical cancer, cervical cytology screening reduces both the incidence of, and mortality from, cervical cancer by detecting pre-invasive, treatable lesions. 5. In asymptomatic women at average risk of malignancy, a visual and bimanual examination at the time of obtaining cervical cytology samples may add value to this screening manoeuvre: Women might not raise certain gynaecologic concerns until the time of pelvic examination; the examination provides an opportunity for patient education and practitioner skill maintenance; and, although inadequately studied to date, there may be positive effects on ovarian and vulvar malignancy that require further investigation. These potential benefits should be weighed against potential harms like patient discomfort and false positives/negatives that may result in inappropriate reassurance or unnecessary investigations/interventions.

RECOMMENDATIONS: Symptomatic Women. 1) Any woman with gynaecologic complaints including, but not limited to, vulvar complaints, vaginal discharge, abnormal premenopausal bleeding, postmenopausal bleeding, infertility, pelvic organ prolapse symptoms, urinary incontinence, new and unexplained gastrointestinal symptoms (abdominal pain, increased abdominal size/bloating, and difficulty eating/early satiety), pelvic pain, or dyspareunia should undergo appropriate components of the pelvic examination to identify benign or malignant disease (strong, low). 2) Health care providers may consider discussing the risks and benefits of performing a baseline pelvic examination including visual and bimanual examination prior to prescribing hormonal replacement therapy/menopausal hormonal treatment (weak, very low). Asymptomatic Women. 3) Health care practitioners should perform cervical cytology cancer screening in accordance with provincial/territorial guidelines (strong, strong). 4) There is insufficient evidence to guide recommendations on screening pelvic examination for noncervical gynaecologic malignancy or any benign gynaecologic disease in healthy, asymptomatic women with average risk of malignancy. However, health care practitioners may consider performing a screening pelvic examination including visual, speculum, and bimanual examinations in concert with cervical cytology sampling intervals as recommended by provincial/territorial guidelines. This practice may identify clinically important benign or malignant disease not recognized or reported by the patient (weak, very low). 5) In women over age 70 who no longer require screening with cervical cytology, health care practitioners should consider continuing periodic screening of asymptomatic women for vulvar disease with inspection of the vulva, perineum, and anus to identify benign or malignant disease unrecognized by this population. There is insufficient evidence to guide recommendations on frequency of this examination (weak, low). 6) Women with a personal history of gynaecologic malignancy, a genetic diagnosis that increases gynaecologic malignancy risk, or a history of in utero diethylstilbestrol exposure may benefit from more frequent screening pelvic examinations to identify early primary, recurrent, or metastatic malignancy in the absence of symptoms. Because there is inadequate evidence to define these screening intervals, they should be in accordance with provincial/territorial guidelines and expert opinion (weak, very low). 7. Non-invasive and self-collection screening options for chlamydia and gonorrhea are acceptable in asymptomatic women, but pelvic examination, including visual inspection, speculum examination, and bimanual examination, is required in the presence of symptoms to rule out pelvic inflammatory disease or tubo-ovarian abscess (strong, low). 8) No pelvic examination is required prior to prescription of hormonal contraception in a healthy woman with no gynaecologic symptoms (strong, low).

来源:J Obstet Gynaecol Can,查看原文。版权归原作者所有。

参考来源

  1. Evans D, Goldstein S, Loewy A, et al. No. 385-Indications for Pelvic Examination. J Obstet Gynaecol Can. 2019. PMID: 31331610. doi:10.1016/j.jogc.2018.12.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。